DK0781341T3 - Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler - Google Patents

Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler

Info

Publication number
DK0781341T3
DK0781341T3 DK95931242T DK95931242T DK0781341T3 DK 0781341 T3 DK0781341 T3 DK 0781341T3 DK 95931242 T DK95931242 T DK 95931242T DK 95931242 T DK95931242 T DK 95931242T DK 0781341 T3 DK0781341 T3 DK 0781341T3
Authority
DK
Denmark
Prior art keywords
plasmids
pct
preparation
recombinant proteins
modified cells
Prior art date
Application number
DK95931242T
Other languages
Danish (da)
English (en)
Inventor
Beatrice Cameron
Joeel Crouzet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK0781341T3 publication Critical patent/DK0781341T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK95931242T 1994-09-16 1995-09-14 Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler DK0781341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411049A FR2724665B1 (fr) 1994-09-16 1994-09-16 Procede de production de proteines recombinantes, plasmides et cellules modifiees
PCT/FR1995/001178 WO1996008572A1 (fr) 1994-09-16 1995-09-14 Procede de production de proteines recombinantes, plasmides et cellules modifiees

Publications (1)

Publication Number Publication Date
DK0781341T3 true DK0781341T3 (da) 2009-01-05

Family

ID=9466987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95931242T DK0781341T3 (da) 1994-09-16 1995-09-14 Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler

Country Status (19)

Country Link
US (1) US6143518A (xx)
EP (1) EP0781341B1 (xx)
JP (1) JP3696247B2 (xx)
KR (1) KR100391752B1 (xx)
AT (1) ATE405656T1 (xx)
AU (1) AU708080B2 (xx)
CA (1) CA2197804C (xx)
DE (1) DE69535815D1 (xx)
DK (1) DK0781341T3 (xx)
ES (1) ES2313721T3 (xx)
FI (1) FI120238B (xx)
FR (1) FR2724665B1 (xx)
IL (1) IL115308A (xx)
MX (1) MX9701614A (xx)
NO (1) NO320374B1 (xx)
PT (1) PT781341E (xx)
TW (1) TW517086B (xx)
WO (1) WO1996008572A1 (xx)
ZA (1) ZA957750B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618001D0 (en) 1996-08-29 1996-10-09 Nyfotek As Novel expression vectors
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
EP1022337B1 (en) * 1999-01-20 2006-07-26 Bayer HealthCare AG Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins
EP1022339B1 (en) 1999-01-20 2006-02-01 Bayer HealthCare AG Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins
BR9917526B1 (pt) * 1999-10-19 2013-09-24 construção de expressão para transformar um hospedeiro unicelular, célula de hospedeiro unicelular bem como método de produzir endopeptidase de lisostafina madura livre de preprolisostafina e prolisostafina
JP5650368B2 (ja) * 2005-10-27 2015-01-07 株式会社カネカ 新規プラスミドベクター及びプラスミドを安定に保持する形質転換体
US9051589B2 (en) * 2005-10-27 2015-06-09 Kaneka Corporation Plasmid vector and transformant stably retaining plasmid
KR20110014199A (ko) 2008-05-13 2011-02-10 클라라산스, 인크. 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
BR102014014502B1 (pt) * 2014-06-13 2020-09-15 Ouro Fino Saúde Animal Ltda Vetor de expressão

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
US5175147A (en) * 1988-08-19 1992-12-29 Takeda Chemical Industries, Ltd Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
FR2642086B1 (fr) * 1989-01-26 1992-09-04 Sanofi Sa Gene recombinant codant pour un facteur basique de croissance des fibroblastes et ledit facteur
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
FR2661188B1 (fr) * 1990-04-24 1994-07-22 Rhone Poulenc Sante Nouveaux vecteurs de clonage et/ou d'expression, procede de preparation et leur utilisation.

Also Published As

Publication number Publication date
IL115308A0 (en) 1995-12-31
PT781341E (pt) 2008-11-20
ZA957750B (en) 1996-04-24
IL115308A (en) 2009-07-20
ES2313721T3 (es) 2009-03-01
KR100391752B1 (ko) 2003-10-22
FI971100A0 (fi) 1997-03-14
CA2197804C (fr) 2010-11-16
EP0781341A1 (fr) 1997-07-02
FI120238B (fi) 2009-08-14
FR2724665A1 (fr) 1996-03-22
DE69535815D1 (de) 2008-10-02
NO971139D0 (no) 1997-03-12
WO1996008572A1 (fr) 1996-03-21
EP0781341B1 (fr) 2008-08-20
NO971139L (no) 1997-03-12
FR2724665B1 (fr) 1996-12-20
AU708080B2 (en) 1999-07-29
NO320374B1 (no) 2005-11-28
TW517086B (en) 2003-01-11
AU3475495A (en) 1996-03-29
US6143518A (en) 2000-11-07
ATE405656T1 (de) 2008-09-15
FI971100A (fi) 1997-03-14
JPH10505746A (ja) 1998-06-09
MX9701614A (es) 1997-06-28
JP3696247B2 (ja) 2005-09-14
CA2197804A1 (fr) 1996-03-21

Similar Documents

Publication Publication Date Title
DK0575443T3 (da) Ærteproteinhydrolysat, fremgangsmåde til dets fremstilling og anvendelse deraf
DE50013610D1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
ATE177473T1 (de) Herstellung von rekombinanten, menschlichem lactoferrin
FI950628A0 (fi) Modifioidut sienisolut ja menetelmä rekombinanttituotteiden tuottamiseksi
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
DK0781341T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler
HU9200548D0 (en) Improved activity process of recombined proteins
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
NO971621L (no) Keratinocyttvekstfaktoranaloger
EP0546087A4 (xx)
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
ES2114555T3 (es) Nuevo interferon gamma humano recombinado.
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ES2033212A6 (es) Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados.